Monday, May 23, 2022
Distribution: (800) 510 0384
Washington DC
New York
Toronto
Press ID  
  • Login
The Hudson Weekly
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity
No Result
View All Result
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity
No Result
View All Result
The Hudson Weekly
No Result
View All Result

FDA Accepts BioMarin’s New Drug Application for Vosoritide to Treat Children with Achondroplasia

If approved, 1st Therapy in U.S. for the Treatment of Achondroplasia. PDUFA Action Date is Aug. 20, 2021

Emily Manifold by Emily Manifold
November 18, 2020
in Health
A A
FDA Accepts BioMarin’s New Drug Application for Vosoritide to Treat Children with Achondroplasia

© FDA

Share on FacebookShare on Twitter

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. This acceptance by the FDA marks the first marketing application accepted for a treatment for achondroplasia in the United States

The Prescription Drug User Fee Act (PDUFA) action date is Aug. 20, 2021. The FDA has informed the company that they are not currently planning to hold an advisory committee meeting to discuss the application.

HudsonNewsroom

The Abbott BinaxNOW COVID-19 Test – Everything You Need to Know About It

Smarmore Castle: When a Habit Becomes an Addiction

Antoine Skaff and His American Success Story (Exclusive Interview)

Although the FDA did not identify any filing issues with the NDA, the Agency reiterated a position raised during the Pediatric Advisory Committee (PAC) and Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) held on May 11, 2018 recommending two-year controlled trials in different age groups. BioMarin believes the highly persuasive outcomes from the one-year randomized, double-blind, placebo-controlled Phase 3 trial, coupled with data from the Phase 2 program with up to 5 years of long-term follow-up that has been compared to robust natural history data on growth, offers a rigorous and reliable method to assess whether vosoritide has a durable impact on the rate of endochondral bone growth that ultimately increases final adult height. This information was included in the marketing application.

While not part of the vosoritide marketing application, in Q4, the Company is also expecting to complete enrollment in a Phase 2 randomized, placebo-controlled study of vosoritide in approximately 70 infants and young children with achondroplasia, aged zero to less than 60 months, for a period of 52 weeks. The study will be followed by a subsequent open-label extension trial when all subjects receive active treatment. Children in this study will complete a minimum three-month baseline study to determine their respective baseline growth prior to dosing in the Phase 2 study. Children in this study will have completed a minimum three-month baseline study to determine their respective baseline growth prior to entering the Phase 2 study. The primary objectives of the study are to evaluate safety, tolerability, and the effect of vosoritide on height Z-scores, which is the number of standard deviations in relation to the mean height of age-matched, average stature children. The company also plans to augment the height Z-score data with assessments including proportionality, functionality, quality of life, sleep apnea, and foramen magnum dimension, as well as the advent of major illnesses and surgeries.

“We are looking forward to working with the FDA and other regulatory authorities to evaluate the safety and efficacy of the potentially first pharmacological treatment for children with achondroplasia. In addition to the completed clinical studies included in the application, we have included a natural history study to understand the progression of achondroplasia and medical implications,” said Hank Fuchs, M.D., President Worldwide Research and Development at BioMarin. “Our extensive development program has been focused on addressing the underlying cause of achondroplasia. We continue to respect the community’s range of views around treatment options. We are grateful to the families who have participated in the clinical trials, the advocacy groups from around the world, and the study investigators, all who have been on this journey with us to deliver a treatment choice and contribute to further understanding achondroplasia medically and scientifically.”

“This is important progress that could lead to the first pharmacological treatment of the underlying cause of achondroplasia. As a treating physician, I feel that it is very important that such treatment options become available to families who may want to consider them for their child,” said John A. Phillips III, M.D., Vanderbilt University Medical Center (David T Karzon Professor of Pediatrics) and investigator for the vosoritide clinical program. “The comprehensive clinical program for vosoritide provides scientific and clinical knowledge that focuses on the safety and efficacy of vosoritide and better understanding of the basic cause of achondroplasia, its natural history and treatment.”

“We are hopeful that our community is one step closer to having access to the first therapeutic choice for children and families affected by achondroplasia,” said Munira Haider, co-founder of Growing Stronger. “We advocate for rigorous scientific and medical research to improve the quality of medical care for little people.”

Growing Stronger’s mission is to improve the quality of medical care for people through supporting research. The organization raises nonprofit donations that are granted to researchers focused on dwarfism.

Regulatory Status in the U.S. and Europe

BioMarin previously announced that the European Medicines Agency (EMA) validated the Company’s Marketing Authorization Application. Vosoritide has also received orphan drug designation from the FDA and EMA for the treatment of children with achondroplasia. The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

Emily Manifold

Emily Manifold

Newsdesk Assistant Editor

More from HW Newsdesk

The Abbott BinaxNOW COVID-19 Test - Everything You Need to Know About It
Health

The Abbott BinaxNOW COVID-19 Test – Everything You Need to Know About It

May 18, 2022
Smarmore Castle: When a Habit Becomes an Addiction
Health

Smarmore Castle: When a Habit Becomes an Addiction

May 17, 2022
Antoine Skaff and His American Success Story (Exclusive Interview)
Health

Antoine Skaff and His American Success Story (Exclusive Interview)

May 12, 2022

HW Newsroom

BFK Warzone: One of the First 2D P2E Shooter Games on the Blockchain?
Blockchain

BFK Warzone: One of the First 2D P2E Shooter Games on the Blockchain?

by Ryan Offman
May 17, 2022

Play-to-Earn gaming (P2E) has become very popular over the last few years, and during this time, the market has seen...

Smarmore Castle: When a Habit Becomes an Addiction

Smarmore Castle: When a Habit Becomes an Addiction

May 17, 2022
The Rise in Cryptocurrency Addiction

The Rise in Cryptocurrency Addiction

May 17, 2022
Fragile Tomorrow Releases New Single and Video 'Lost in Art' Ahead of Forthcoming Album

Fragile Tomorrow Releases New Single and Video ‘Lost in Art’ Ahead of Forthcoming Album

May 16, 2022
Crystal House Miami Designs Luxurious, One-of-a-Kind Crystal Spaces for Miami's Elite

Crystal House Miami Designs Luxurious, One-of-a-Kind Crystal Spaces for Miami’s Elite

May 16, 2022
Monique Melton's Black Liberation Challenge Asks Every Corporation to Honor Juneteenth With a Commitment to Anti-Racism

Monique Melton’s Black Liberation Challenge Asks Every Corporation to Honor Juneteenth With a Commitment to Anti-Racism

May 16, 2022
Chamco Digital on Offering Innovative Digital Solutions and Technologies

Chamco Digital on Offering Innovative Digital Solutions and Technologies

May 16, 2022
Hard Times at Starboard: The King of Activist Hedge Funds Hits a Rough Patch

Hard Times at Starboard: The King of Activist Hedge Funds Hits a Rough Patch

May 14, 2022
That Witch Beauty and Kitsie Duncan’s Inspiration Behind Her Anti-Aging, Self Care Beauty Brand

That Witch Beauty and Kitsie Duncan’s Inspiration Behind Her Anti-Aging, Self Care Beauty Brand

May 14, 2022
Surgical Steel Earrings: Safe Anti-Allergy Material

Surgical Steel Earrings: Safe Anti-Allergy Material

May 14, 2022
$3.925 Million Golf-Front Estate is Highest-Priced Sale in The History Of Treviso Bay

$3.925 Million Golf-Front Estate is Highest-Priced Sale in The History Of Treviso Bay

May 14, 2022
The FieldTurf Legend Continues at the University of Nebraska

The FieldTurf Legend Continues at the University of Nebraska

May 14, 2022
No Result
View All Result

Headlines

From Struggling for Money to Financial Independence, With Luis Alvarado, the Founder of Unlimited Leverage

Don Daniel Teams Up With an All-Star Cast for the Money Mindset Event of the Year! Special Keynote: Eric Thomas

The Abbott BinaxNOW COVID-19 Test – Everything You Need to Know About It

BFK Warzone: One of the First 2D P2E Shooter Games on the Blockchain?

Smarmore Castle: When a Habit Becomes an Addiction

The Rise in Cryptocurrency Addiction

Trending

Squeeze Bolsters Executive Leadership Team With Patrick Murphy as New Chief Financial Officer
Financial

Squeeze Bolsters Executive Leadership Team With Patrick Murphy as New Chief Financial Officer

by Emily Manifold
May 19, 2022

Squeeze, the leading Sales Experience (SX) provider, announces the appointment of Patrick Murphy as its new Chief...

MASS Group Awarded a Contract From Oakland County (Michigan) for Primary Inventory Management Solution

MASS Group Awarded a Contract From Oakland County (Michigan) for Primary Inventory Management Solution

May 19, 2022
From Struggling for Money to Financial Independence, With Luis Alvarado, the Founder of Unlimited Leverage

From Struggling for Money to Financial Independence, With Luis Alvarado, the Founder of Unlimited Leverage

May 18, 2022
Don Daniel Teams Up With an All-Star Cast for the Money Mindset Event of the Year! Special Keynote: Eric Thomas

Don Daniel Teams Up With an All-Star Cast for the Money Mindset Event of the Year! Special Keynote: Eric Thomas

May 18, 2022
The Abbott BinaxNOW COVID-19 Test - Everything You Need to Know About It

The Abbott BinaxNOW COVID-19 Test – Everything You Need to Know About It

May 18, 2022
  • Statement by U.S. Conference of Mayors on Mass Shooting in Buffalo

https://ritzherald.com/statement-by-u-s-conference-of-mayors-on-mass-shooting-in-buffalo/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr
  • Sea Ice Can Control Antarctic Ice Sheet Stability, New Research Finds

https://ritzherald.com/sea-ice-can-control-antarctic-ice-sheet-stability-new-research-finds/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr #sealevelrise
  • USW Announces Tentative Agreement With Arconic on Four-Year Contract

https://ritzherald.com/usw-announces-tentative-agreement-with-arconic-on-four-year-contract/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr
  • MOZAIK Philanthropy Announces Open Call for Digital Art

https://ritzherald.com/mozaik-philanthropy-announces-open-call-for-digital-art/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr #digitalartist
  • Southwestern Association for Indian Arts Announces Centennial Fashion Designers

https://ritzherald.com/southwestern-association-for-indian-arts-announces-centennial-fashion-designers/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr
  • Unreleased Live Concert of Ella Fitzgerald Performing Songs From Her Beloved Irving Berlin Songbook

https://ritzherald.com/unreleased-live-concert-of-ella-fitzgerald-performing-songs-from-her-beloved-irving-berlin-songbook/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr #ellafitzgerald
  • Cedars-Sinai Leader in Maternal-Fetal Medicine Honored for Dedication to Women’s Healthcare

https://ritzherald.com/cedars-sinai-leader-in-maternal-fetal-medicine-honored-for-dedication-to-womens-healthcare/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr
  • IAPMO Supports U.S. Sen. Tammy Baldwin’s Healthy Drinking Water Affordability Act

https://ritzherald.com/iapmo-supports-u-s-sen-tammy-baldwins-healthy-drinking-water-affordability-act/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #marketingstrategy #marketingdigital #guestpost #guestposting #marketingtips #pr

© 2022 The Hudson Weekly. Published by The Ritz Herald. Editions: Markets Herald • Lincoln Citizen • Madison Graph • Belmont Star • Fairmont Post

Address: 1177 6th Avenue, 5th Floor, New York, NY 10036. Contact: pr@hudsonweekly.com. Phone: (718) 313-5252. M-F: 9AM-5PM. Privacy Policy

No Result
View All Result
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist